Comparative Pharmacology
Head-to-head clinical analysis: FEXINIDAZOLE versus NITAZOXANIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXINIDAZOLE versus NITAZOXANIDE.
FEXINIDAZOLE vs NITAZOXANIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
Interferes with pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reactions, essential for anaerobic metabolism in certain pathogens.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
500 mg orally twice daily for 3 days for treatment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia; for chronic giardiasis, 500 mg twice daily for 10 days.
None Documented
None Documented
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
The terminal elimination half-life of the active metabolite tizoxanide is approximately 1.5–2 hours in adults and 2–4 hours in children. Clinical context: The short half-life supports twice-daily dosing; accumulation is minimal with normal dosing intervals.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Nitazoxanide is primarily excreted in feces (approximately 66%) and urine (approximately 33%). Renal elimination accounts for about 33% of the dose, primarily as the active metabolite tizoxanide (glucuronide conjugates), while fecal excretion accounts for approximately 66%, mostly as tizoxanide and its conjugates.
Category C
Category A/B
Antiprotozoal
Antiprotozoal